Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine-containing chemotherapy. The purpose of this study was to assess the efficacies of various prevention and treatment strategies for capecitabine-induced HFS. Searches of the PubMed and Embase databases were performed to identify relevant studies. The risk ratio (RR) with the corresponding 95% confidence interval (CI) was used as an effect measure to evaluate the efficacies of these prevention and treatment strategies. Publication bias was evaluated using Begg's and Egger's tests. Overall and subgroup analyses were conducted. All statistical analyses were conducted with Stata software version 12.0. Seventeen eligible studies were included. Our results indicated that celecoxib was significantly associated with a lower incidence of grade 2 capecitabine-induced HFS without heterogeneity (RR 5 0.43, 95% CI 5 0.23-0.81, I
toward preventing capecitabine-induced grade 1, 2, 3, 1 or 2 HFS. Moreover, pyridoxine was not effective in treating capecitabine-induced HFS. Similar results were obtained by subgroup analysis. Our results indicate that celecoxib has potential prophylactic efficacy for capecitabine-induced HFS. However, pyridoxine and topical urea/lactic acid are not associated with a decrease in the incidence of capecitabine-induced HFS.
Capecitabine, an oral fluoropyrimidine, is the prodrug of 5-fluorouracil (5-FU) and is therefore completely absorbed in the gastrointestinal tract and preferentially activated in tumor tissues. 1, 2 Capecitabine can imitate the action of continuous 5-FU infusion and is an integral part of chemotherapy for the treatment of various malignancies, including colorectal cancer, gastric cancer and breast cancer. 1 Capecitabine is usually well-tolerated because of the absence of systemic 5-FU exposure, but capecitabine can cause side effects. Among these, hand-foot syndrome (HFS) is the most common adverse event of capecitabine-containing chemotherapy. HFS-also known as palmar-plantar erythrodysesthesia, palmar-plantar erythema, acral erythema and Burgdorf's reaction-is a distinctive and relatively common dermatologic toxic reaction to certain chemotherapeutic drugs. 3, 4 The severity of HFS symptoms depends on the drug dose, peak concentration and total cumulative dose. 5 Therefore, HFS can lead to the cessation of therapy or a dose reduction and adversely affects quality of life and treatment efficacy, although HFS is usually not life-threatening. 4, 6, 7 Several clinical trials have evaluated different drugs, including pyridoxine, topical urea/lactic acid and a cyclooxygenase-2 (COX-2) inhibitor, for the management of capecitabineinduced HFS [8] [9] [10] [11] [12] ; however, the efficacies of prevention and treatment strategies remain controversial.
The purpose of this study was to assess the efficacies of prevention and treatment strategies for capecitabine-induced HFS and report the incidence of capecitabine-induced HFS.
Materials and Methods

Literature search
Relevant studies on the efficacies of prevention and treatment strategies for capecitabine-induced HFS were identified by systematically searching the PubMed and Embase databases until July 2017. The search terms were "hand-foot syndrome," "hand foot syndrome," "HFS," "palmar-plantar erythrodysesthesia," "palmar plantar erythrodysesthesia," "PPE," "palmar-plantar erythema," "palmar plantar erythema," "acral erythema," "Burgdorf's reaction," "capecitabine" and "Xeloda." In addition, potential studies were identified by manually searching the reference lists of relevant studies and reviews.
Inclusion criteria
The objective of this study was to assess capecitabine-induced HFS rather than the efficacy of capecitabine-containing chemotherapy. Therefore, the studies that were eligible for inclusion in this meta-analysis met the following criteria: (1) patients had received single-agent capecitabine chemotherapy or capecitabine-containing combination chemotherapy for any cancer, as either neoadjuvant, adjuvant or palliative therapy; (2) the studies addressed interventions of interest, namely, prevention and treatment strategies (i.e., pyridoxine, topical urea/lactic acid and celecoxib) versus placebo for capecitabine-induced HFS; (3) preventive/prophylactic efficacy was defined as the difference in the incidence of capecitabine-induced HFS between treatment and placebo groups, and treatment efficacy was defined as the difference in the proportion of symptom improvement in the patients who had developed capecitabine-induced HFS during chemotherapy; (4) the studies addressed outcomes of interest, namely, the incidence of capecitabine-induced HFS and the proportion of symptom improvement; (5) the study types were randomized clinical trials (RCTs) and cohort trials that had been peer-reviewed and published; and (6) the outcome measures and corresponding 95% confidence interval (CI) could be extracted. In cases where several duplicated studies based on the same population or database were identified, the most recent study was included in this meta-analysis.
Exclusion criteria
The exclusion criteria were (1) animal or in vitro studies; (2) studies involving patients previously treated for HFS; (3) studies with <30 patients; (4) studies whose outcomes of interest were not reported or could not be calculated from the published data; (5) duplicate studies based on the same population or database. The inclusion of duplicate studies was avoided by checking all authors, institutions and the accrual period and community of patients for each study.
Data extraction
The eligible studies were reviewed, and data were independently extracted by two authors (Xuan Zhang Huang and You Chen). The following data were extracted from each study: first author, publication year and country, study design, prevention and treatment strategy, sample size, patient sex and age, chemotherapy regimen and capecitabineinduced HFS grade with the corresponding incidence. Any disagreements on data extraction were resolved by discussion.
Statistical analysis
The risk ratio (RR) with the corresponding 95% CI was used as an effect measure to evaluate the prophylactic efficacies of prevention strategies for capecitabine-induced HFS. Treatment efficacy was also evaluated in patients who developed capecitabine-induced HFS during chemotherapy. The overall analysis was conducted by including all relevant studies, and the subgroup analysis was stratified by study design, publication country, drug dose, sample size and capecitabineinduced HFS grade.
Heterogeneity between studies was assessed using the Cochran Q test and I 2 statistic, and significant heterogeneity was defined as I 2 > 50% and/or p < 0.05. 13 A random-effects model was used for meta-analysis if there was significant heterogeneity between studies; otherwise, a fixed-effects model was used. Publication bias was assessed using Begg's and Egger's tests, 14, 15 and trim-and-fill analysis was performed to assess the effect of publication bias if there was significant publication bias.
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A two-sided p < 0.05 was considered statistically significant. All statistical analyses were conducted using Stata software version 12.0 (Stata Corporation, College Station, TX, USA).
Results
Study selection and study characteristics
A total of 4682 studies were initially identified from the literature search, of which 4414 were excluded after reviewing the titles and abstracts. The remaining 268 studies were further analyzed based on a full-text review, and 251 studies were excluded according to the inclusion and exclusion criteria. A total of 17 studies were included in this meta-analysis (Figure 1) . [8] [9] [10] [11] [12] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] These studies were published from 2002 to 2017 in the United States, Germany, United Kingdom, Singapore, China, What's new? Capecitabine is effective against breast, colorectal and gastric cancers and can be orally administered, making it an appealing therapeutic option. Its use, however, can be limited by the development of hand-foot syndrome (HFS), a common side effect that negatively impacts quality of life. The effectiveness of HFS prevention strategies is unclear. The authors of this study evaluated previously reported prevention and treatment strategies for capecitabine-induced HFS. Celecoxib was associated with reduced occurrence of grade 2 or higher HFS, while pyridoxine did not significantly improve HFS symptoms and topical urea/lactic acid was found to be ineffective in preventing the condition.
Iran, Japan, Korea and Thailand. A total of 2081 patients (mean sample size: 122; median sample size with corresponding range: 106 ) were included in this meta-analysis. Of the eligible studies, 12 were RCTs, [9] [10] [11] [12] 18, [20] [21] [22] [23] [24] [25] [26] and five were cohort studies. 8, 17, 19, 27, 28 Fifteen studies only assessed the prophylactic efficacies of prevention strategies, [8] [9] [10] [11] [12] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] and two studies assessed prophylactic and treatment efficacies. 11, 27 The following prevention strategies were addressed in the analyzed studies: pyridoxine (10 studies) 8, 11, 12, [19] [20] [21] [22] 24, 26, 27 ; topical urea/ lactic acid (three studies) 8, 10, 25 ; celecoxib (two studies) 9, 28 ; and moisturizing cream, topical silymarin, Fuzheng Jiedusan and neurotropin (four studies). [17] [18] [19] 23 The main characteristics of the included studies are shown in Table 1 .
Prophylactic efficacy of pyridoxine
Our results indicated that pyridoxine could not reduce the incidence of grade 1, 2, or 3 capecitabine-induced HFS, with insignificant heterogeneity ( Figure 2B ). Similar results were obtained in the subgroup analysis after stratifying by study design, publication country, drug dose and sample size, indicating that pyridoxine did not prevent capecitabineinduced HFS (Table 2) .
One RCT compared the prophylactic efficacy of a daily use with 400 or 200 mg of pyridoxine toward preventing capecitabine-induced HFS, 26 and the results indicated that a high dose of pyridoxine tended to reduce the incidence of grade 2 HFS.
Prophylactic efficacy of celecoxib
Two studies assessed the preventive efficacy of celecoxib for capecitabine-induced HFS. 9, 28 The overall result indicated that celecoxib was significantly associated with a lower incidence of grade 2 HFS, without heterogeneity (RR 5 0.43, 95% CI 5 0.23-0.81, I
2 5 0.0%; Figure 3 ). Moreover, both studies reported that celecoxib could significantly reduce the incidence of grade 1 HFS (p 5 0.034 and p 5 0.037). Therefore, the nonsignificance of the overall results for grade 1 HFS may be due to significant heterogeneity (I 2 5 53.7%) and the use of a conservative random-effects model. 
Prophylactic efficacy of other strategies
Four studies individually assessed the preventive efficacies of moisturizing cream, topical silymarin, Fuzheng Jiedusan and neurotropin for capecitabine-induced HFS. [17] [18] [19] 23 Elyasi et al. reported that the prophylactic use of topical silymarin significantly reduced severe capecitabine-induced HFS. 18 Zhou et al. indicated that the herbal medicine of Fuzheng Jiedusan decreased the incidence of capecitabine-induced HFS (RR 5 0.50, 95% CI 5 0.30-0.84). 17 However, neurotropin and moisturizing cream were not effective toward preventing capecitabine-induced HFS. 19, 23 Treatment efficacy of pyridoxine Two studies evaluated the treatment efficacy of pyridoxine in patients who developed capecitabine-induced HFS during chemotherapy. 11, 27 The overall results indicated that pyridoxine did not improve the capecitabine-induced HFS grade (RR 5 2.47, 95% CI 5 0.49-12.49) and that substantial heterogeneity was present (I 2 5 89.8%). 
Assessment of publication bias
The results of Begg's and Egger's tests indicated that there was no strong evidence of publication bias, except in the subgroup analysis of pyridoxine-based RCT (P Begg's 5 0.089, P Egger's 5 0.002). Furthermore, the trim-and-fill analysis indicated that publication bias did not affect the results (RR 5 0.92, 95% CI 5 0.77-1.11).
Discussion
HFS is a common dose-limiting and dose-dependent side effect that is cause by capecitabine toxicity. In clinical practice, the main treatment for HFS is therapy discontinuation followed by dose reduction. Although the capecitabine dose is reduced, HFS symptoms may progress rapidly due to continuous exposure to capecitabine in cases for which treatment is not interrupted. 4 Moreover, clinical guidelines indicate that a treatment with a dose reduction should be interrupted until the symptoms improve to grade 0 or 1. Treatment modification can adversely affect treatment efficacy and the survival benefit. Therefore, optimum prevention and treatment strategies for capecitabine-induced HFS are needed to improve quality of life and treatment efficacy. This meta-analysis included 17 eligible studies involving 2081 patients. The overall results indicated that celecoxib use had prophylactic efficacy for grade 2 HFS, without heterogeneity (RR 5 0.43, 95% CI 5 0.23-0.81, I 2 5 0.0%). The nonsignificance of the overall results for grade 1 HFS may be because of significant heterogeneity (I 2 5 53.7%) and the use of a conservative random-effects model. However, pyridoxine and topical urea/lactic acid were not effective toward preventing capecitabine-induced grades 1, 2, 3, 1 and 2 HFS. Similar results were obtained in subgroup analysis. In addition, only two studies explored the treatment efficacies of pyridoxine for capecitabine-induced HFS during chemotherapy, and the overall results indicated that treatment for this condition did not improve significantly.
Although the mechanism of capecitabine-induced HFS is not fully understood, several studies have hypothesized that HFS is an inflammatory process caused by COX-2 activation in the hands and feet. 29 Therefore, the use of COX-2 inhibitors may prevent capecitabine-induced HFS. In this respect, Lin et al. conducted a retrospective study to compare the incidence and severity of HFS in 67 patients with metastatic colorectal cancer subjected to capecitabine therapy with or without celecoxib and reported that the capecitabine/celecoxib group had a significantly lower frequency of grade 1 HFS (12.5% vs. 34.3%, p 5 0.037) and a nonsignificant but marked reduction in grade 2 HFS (3.1% vs. 17.1%, p 5 0.11) compared with the capecitabine-alone group. 28 Moreover, Zhang et al. performed a phase II RCT to assess the prophylactic efficacy of celecoxib on capecitabine-induced HFS in 101 stage II and III colorectal cancer patients and observed that celecoxib significantly reduced the incidence of grade 1 (29% vs. 72% p < 0.001) and grade 2 (11.76% vs. 30%, p 5 0.024) HFS. 30 These results were confirmed by Zhang et al. in a phase III RCT. 9 Moreover, several studies have demonstrated that the expression of COX-2 is upregulated in several cancers, suggesting that celecoxib may possess anticancer properties. [31] [32] [33] [34] [35] Therefore, further large-scale studies are needed to explore the prophylactic efficacy of celecoxib for capecitabine-induced HFS and the anticancer activity of celecoxib in capecitabine chemotherapy. Surprisingly, pyridoxine was empirically used to prevent and treat capecitabine-induced HFS because HFS has been found to resemble acrodynia caused by pyridoxine deficiency in rats. [36] [37] [38] Although clinicians have commonly used pyridoxine for HFS, the prophylactic efficacy of pyridoxine for capecitabine-induced HFS was unknown because of the lack of reliable data and evidence. Kang et al. conducted a randomized, double-blind, placebo-controlled trial with 360 patients who were randomized to treatment with either 100 mg of pyridoxine twice daily or placebo, and the results Cancer Therapy and Prevention demonstrated that pyridoxine was not effective toward preventing capecitabine-induced HFS. 11 Similarly, a randomized, double-blind, placebo-controlled phase III trial by Yap et al. involving 210 patients subjected to capecitabine monotherapy showed that pyridoxine did not significantly prevent or delay the onset of capecitabine-induced HFS. 12 Our meta-analysis indicated that pyridoxine did not considerably improve the prophylactic and treatment efficacy for capecitabine-induced HFS.
Because the daily dose of pyridoxine was <250 mg in the included studies and our subgroup analysis indicated that pyridoxine doses of <200 and 200 mg did not have , degree of heterogeneity; N, the number of studies; P, P for the RR; RCT, randomized clinical trials; RR, relative risk; "/", not applicable due to limited number of studies. Cancer Therapy and Prevention prophylactic efficacy for capecitabine-induced HFS, whether a higher dose of pyridoxine is effective against capecitabineinduced HFS remains unknown. A randomized trial by Chalermchai et al. using two different doses of pyridoxine indicated that patients receiving a daily dose of 400 mg of pyridoxine combined with capecitabine had a significantly lower incidence of HFS than those who received 200 mg. 26 However, the potential side effects caused by high doses of pyridoxine were also a cause for concern during clinical treatment. Therefore, further large-scale RCTs are necessary to evaluate the efficacy and safety of high doses of pyridoxine. Moreover, several studies investigated the clinical predictors of capecitabine-induced HFS and reported that hemoglobin, serum and red blood cell folate levels were important factors for developing HFS. 12, 19 Therefore, the incidence of capecitabine-induced HFS may be improved by targeting these clinical predictors.
With respect to other prevention strategies, four studies independently evaluated moisturizing cream, topical silymarin, Fuzheng Jiedusan and neurotropin. Topical silymarin and Fuzheng Jiedusan may reduce the incidence of capecitabine-induced HFS. 17, 18 However, neurotropin and moisturizing cream were not effective in preventing HFS. 19, 23 Because of the low number of trials, additional studies are needed to explore the prophylactic efficacies of other potential prevention strategies for capecitabine-induced HFS.
Previous studies have reported that regional cooling might be effective in preventing HFS caused by chemotherapy drugs, and the theoretical underlying mechanism is vasoconstriction and the consequent decrease in the extravasation of circulating drugs to distal extremities. 39, 40 However, to the best of our knowledge, no studies to date have assessed the efficacy of regional cooling on capecitabine-induced HFS. Most of the analyzed studies focused on HFS induced by Cancer Therapy and Prevention pegylated liposomal doxorubicin (PLD), and the results of these studies were inconsistent. Mangili et al. and Molpus et al. observed that regional cooling reduced the incidence of HFS associated with PLD (p < 0.01 and p 5 0.047, respectively). 39, 40 Julius et al. demonstrated that regional cooling was not associated with a decrease in the incidence of PLDinduced HFS (p 5 0.146), 41 and Tanyi et al. showed that the proportion of PLD-induced HFS cases was significantly higher among patients who used regional cooling than among those who did not (p 5 0.0139). 42 The mechanisms underlying HFS due to capecitabine and PLD may be different, and therefore, an extrapolation of the results from PLD to capecitabine is inappropriate. Further large-scale studies are needed to evaluate the efficacy of regional cooling on capecitabine-induced HFS. In addition, no studies to date have analyzed the efficacies of prevention strategies together with other preventive medications in preventing capecitabineinduced HFS. Conversely, most studies excluded patients subjected to prevention strategies combined with other preventive medications. For this reason, further studies are needed to assess the efficacies of combined prevention strategies on capecitabine-induced HFS.
This study had some limitations. First, pyridoxine, topical urea/lactic acid and celecoxib were analyzed in 10, 3 and 2 studies, respectively. The limited number of studies included in the overall and subgroup analyses may have affected the statistical power of our results. Second, the incidence of grade 3 HFS caused by capecitabine was relatively low (5.8%), and therefore, the limited number of grade 3 events may have affected the strength of our results. Third, heterogeneity among the results could not be completely eliminated or adequately explained. Therefore, the efficacies of prevention and treatment strategies for capecitabine-induced HFS should be confirmed with further large-scale multicenter studies with homogeneous treatment regimens and populations.
In conclusion, our results indicate that celecoxib has potential prophylactic efficacy for capecitabine-induced HFS, and thus, celecoxib may help patients safely complete capecitabine-containing chemotherapy. However, pyridoxine and topical urea/lactic acid are not associated with a decrease in the incidence of capecitabine-induced HFS. Further largescale, high-quality studies are needed to evaluate the prophylactic efficacy of the prevention strategies for capecitabineinduced HFS.
